Topic: inflammatory bowel disease
The agreement tasks Prometheus with identifying and validating three IBD drug targets in return for up to $420 million in milestones.
Finch thinks it has a shot at winning FDA approval of the full-spectrum microbiota drug if the ongoing clinical study generates “compelling results.”
Landos Biopharma picked up $60 million to propel its lead program into phase 2 for ulcerative colitis and Crohn's disease.
Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.
The Bausch Health subsidiary plans to trial the ex-Biogen S1P receptor functional antagonist in ulcerative colitis.
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
Fe3 Medical is moving forward with its wearable patch that uses electrical current to deliver iron directly through the skin.
Synlogic has recruited a new chief scientific officer: Scott Plevy, M.D., who headed up gastroenterology and interleukin-23 research at Janssen.
BiomX raised $32 million for preclinical development of its customized phage cocktail therapies aimed at eradicating the bacteria behind IBD and acne.
Vedanta Biosciences will advance its pipeline of microbiome-derived drugs, including a handful of assets currently in midstage trials.